This technology involves a highly specific monoclonal antibody that recognizes an epitope present on HLA-B27 as well as several related HLA alloantigens, including HLA-B7, Bw42, Bw54, and others. Generated by immunizing mice with targeted lymphoid cell lines, the antibody’s binding site is carefully mapped through comprehensive serologic and immunochemical assays. In addition, antiidiotypic antibodies confirm its exclusive interaction with the targeted antigen determinant. The technology is incorporated into a double determinant immunoassay using an anti-human beta 2-microglobulin antibody, enabling sensitive detection and quantitation of the antigen in various biological samples through techniques such as Western blotting, immunoprecipitation, immunohistochemistry, and flow cytometry.
Description
This approach stands apart due to its precise epitope targeting, which is spatially close to but distinct from those recognized by earlier antibodies. Its unique specificity minimizes cross-reactivity, thereby improving the reliability of HLA-B27 typing. The robust assay design also offers significant improvements in sensitivity and versatility, providing a reliable tool for research and clinical laboratories to accurately detect and study HLA-B27 expression and its associated immunological implications.
Applications
- HLA typing kits
- Immunoassay reagent development
- Flow cytometry antibodies
- Immunohistochemistry reagents
Advantages
- Provides unique specificity for HLA-B27 and related HLA alloantigens, enabling precise immune recognition.
- Facilitates a highly sensitive double determinant immunoassay for detecting and quantifying HLA-B27 in various samples.
- Supports multiple laboratory applications, including Western blotting, immunoprecipitation, immunohistochemistry, and flow cytometry.
- Improves HLA typing crucial for diagnosing autoimmune conditions like ankylosing spondylitis.
IP Status
Research Tool
